ScholarLens Back to search
2002•Shaanxi Oncology MedicineRequires access

Etoposide-ifosfamide-mitoxantrone regimen in treatment of relapsed and refractory non-Hodgkin Lymphoma.

GU Han-gang

Open publisher page 0 citations

Abstract

Objective The current study was designed to observe the efficacy and toxicity of etoposide,ifosfamide and mitoxantrone (VIM) regimen for relapsed and refractory non-Hodgkin's lymphoma. Methods Forty patients with intermediate or high-grade lymphoma were selected as sabjects. Eight patients had refractory disease,the others were relapsed more than twice.All patients received VP-16 65mg/m2,IFO 1.0g/m2 on day 1 to 3 and MIT 8mg/m2 on day 1. Results Overall response rate was 55% (7CR and 15PR) with a median duration of 25 months (range:2-29).The main toxicity was mild mylosuppression. Conclusion The VIM regimen is efficent and safe.

About this research paper

What this paper is about

Objective The current study was designed to observe the efficacy and toxicity of etoposide,ifosfamide and mitoxantrone (VIM) regimen for relapsed and refractory non-Hodgkin's lymphoma. Methods Forty patients with intermediate or high-grade lymphoma were selected as sabjects. Eight patients had refractory disease,the others were relapsed more than twice.All patients received VP-16 65mg/m2,IFO 1.0g/m2 on day 1 to 3 and MIT 8mg/m2 on day 1. Results Overall response rate was 55% (7CR and 15PR) with a median duration of 25 months (range:2-29).The main toxicity was mild mylosuppression. Conclusion The VIM regimen is efficent and safe.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective The current study was designed to observe the efficacy and toxicity of etoposide,ifosfamide and mitoxantrone (VIM) regimen for relapsed and refractory non-Hodgkin's lymphoma. Methods Forty patients with intermediate or high-grade lymphoma were selected as sabjects. Eight patients had refractory disease,the others were relapsed more than twice.All patients received VP-16 65mg/m2,IFO 1.0g/m2 on day 1 to 3 and MIT 8mg/m2 on day 1. Results Overall response rate was 55% (7CR and 15PR) with a median duration of 25 months (range:2-29).The main toxicity was mild mylosuppression. Conclusion The VIM regimen is efficent and safe.

Key concepts: Medicine, Mitoxantrone, Etoposide, Ifosfamide, Regimen, Refractory (planetary science), Internal medicine, Toxicity

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Etoposide-ifosfamide-mitoxantrone regimen in treatment of relapsed and refractory non-Hodgkin Lymphoma. — Research Paper | ScholarLens